Human monoclonal antibodies that neutralize pandemic GII.4 noroviruses
AssigneesVanderbilt University, Baylor College of Medicine
InventorsJames E. Crowe, Jr., Mary Estes
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to antibodies binding to and neutralizing norovirus and methods for use thereof. Thus, in accordance with the present disclosure, there is provided a method of detecting a norovirus infection in a subject comprising (a) contacting a sample from the subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences; and (b) detecting norovirus in the sample by binding of the antibody or antibody fragment to a norovirus antigen in the sample.
Claims21
A method of detecting a norovirus infection in a subject comprising:
- (a) contacting a sample from said subject with an antibody or antigen binding fragment thereof comprising heavy chain CDR1-3 sequences comprising SEQ ID NOS:
- 114-116, and light chain CDR1-3 sequences comprising SEQ ID NOS:
- 165-167;
- and
- (b) detecting norovirus in said sample by binding of said antibody or antigen binding fragment thereof to a norovirus antigen in said sample.
A method of treating a subject infected with norovirus, or reducing the likelihood of infection of a subject at risk of contracting norovirus, comprising delivering to said subject an antibody or antigen binding fragment thereof comprising heavy chain CDR1-3 sequences comprising SEQ ID NOS:
- 114-116, and light chain CDR1-3 sequences comprising SEQ ID NOS:
- 165-167.
A monoclonal antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof comprising heavy chain CDR1-3 sequences comprising SEQ ID NOS:
- 114-116, and light chain CDR1-3 sequences comprising SEQ ID NOS:
- 165-167, wherein said antibody or antigen binding fragment thereof comprises an Fc portion mutated to eliminate or enhance FcR interactions to increase half-life and/or increase therapeutic efficacy or glycan modified to eliminate or enhance FcR interactions.
A hybridoma or engineered cell encoding an antibody or antigen binding fragment thereof wherein the antibody or antigen binding fragment thereof comprising heavy chain CDR1-3 sequences comprising SEQ ID NOS:
- 114-116, and light chain CDR1-3 sequences comprising SEQ ID NOS:
- 165-167.
Dependencies are inferred from the claim text.